With thousands of opioid lawsuits piling up in a Cleveland courthouse, drugmakers and plaintiffs seemed at an impasse on how to move forward. Now, empowered by Endo and Allergan’s deals with two Ohio counties, all parties could be rushing to
read moreAjinomoto Bio-Pharma Services is taking full control of an API manufacturing facility in India as the CDMO continues to bulk up in a market that favors companies that can do it all. More: Ajinomoto Bio-Pharma buys Indian API plant from
read moreSun Pharma might soon escape the whistleblower complaints weighing on its shares. A preliminary probe by India’s securities watchdog, focused primarily on two of the allegations, found no violation of securities laws at the drugmaker. More: Relief for Sun Pharma
read moreNext-gen hepatitis C meds typically cure the disease with few side effects, but the FDA says it’s tracking rare cases of liver damage in patients using some top-selling drugs—mostly patients who shouldn’t have been using them in the first place.
read moreThe Pharmacovigilance Risk Assessment Committee initially recommended new measures in July. More: EMA recommends new methotrexate measures Source: News
read moreThe transaction is expected to close by the end of 2019. More: Amgen to acquire Celgene’s Otezla Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals